Trial Profile
Phase II Evaluation of Nivolumab, an Immune Checkpoint Inhibitor Alone or in Combination With Oral Decitabine/Tetrahydrouridine as Second Line Therapy for Non-small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Apr 2024
Price :
$35
*
At a glance
- Drugs Decitabine (Primary) ; Nivolumab (Primary) ; Tetrahydrouridine (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms PRECISE
- 15 Mar 2024 Planned End Date changed from 14 Feb 2024 to 15 Aug 2024.
- 09 Dec 2020 Status changed from completed to active, no longer recruiting.
- 09 Dec 2020 Planned End Date changed from 13 Jun 2019 to 14 Feb 2024.